Thyroid Cancer Survival Rate UK 2026 by Stage: What the NHS Numbers Actually Mean

More than 84 per cent of UK patients diagnosed with thyroid cancer survive 10 years or more – one of the highest survival rates of any common cancer.

A thyroid cancer diagnosis carries real emotional weight. Even when your consultant explains that survival rates are high, it is hard to hear the word “cancer” and take in much else. That reaction is entirely normal and worth acknowledging before we get into the numbers.

The UK has very high survival rates for most thyroid cancers. Overall, thyroid cancer has the best long-term outlook of any common solid tumour, and the majority of people diagnosed go on to live full, ordinary lives after treatment. But the numbers are not uniform. Survival varies depending on which of the four types of thyroid cancer you have, how far it had spread when it was found, and your age at diagnosis.

This article walks through those differences in plain language. We cover the four thyroid cancer types, the staging system used on the NHS in 2026, five-year and ten-year survival figures by stage, what current NHS treatment looks like, and what the numbers actually mean for an individual person. The aim is to give you clear, evidence-based information so you can have a more informed conversation with your consultant or specialist nurse.

Thyroid cancer in the UK by the numbers

Thyroid cancer accounts for roughly 1 per cent of all cancers diagnosed in the UK each year. That translates to around 4,500 new cases annually, a figure that has been gradually rising over the past two decades, partly because improved imaging picks up smaller tumours that would previously have gone undetected.

The condition is about three times more common in women than in men. The lifetime risk in the UK is approximately 1 in 380 for women and 1 in 1,200 for men. The median age at diagnosis is around 50 years, though thyroid cancer can appear at any age, including in children and teenagers.

The most reassuring figure is the long-term survival rate. According to Cancer Research UK data covering people diagnosed in England between 2013 and 2017, 84.3 per cent of thyroid cancer patients survived ten years or more. That makes thyroid cancer the common solid cancer with the highest ten-year survival in the UK, considerably ahead of breast, prostate and colorectal cancers. One-year survival sits at around 92 to 93 per cent, and five-year survival at around 87 to 88 per cent across all types and stages combined.

Age, however, has a striking effect on outcomes. Among patients diagnosed between the ages of 15 and 44, the ten-year survival rate was 99.2 per cent. Among those diagnosed between 75 and 99, it was 57.7 per cent. Older age at diagnosis is the single strongest negative prognostic factor for thyroid cancer, more influential than stage or even cancer type. Women also fare slightly better than men overall, with around 87 per cent ten-year survival compared to approximately 76 per cent in men, partly because women tend to be diagnosed at a younger average age.

The four types of thyroid cancer

Thyroid cancer is not a single disease. There are four main types, and they differ considerably in how they behave, whom they affect and how treatable they are.

Papillary thyroid cancer is by far the most common, accounting for around 80 per cent of all cases. It tends to grow slowly and is often confined to one lobe of the thyroid when found. It has the best overall outlook of the four types, with five-year survival rates above 95 per cent for most stages.

Follicular thyroid cancer makes up roughly 10 per cent of cases. It is also slow-growing and affects a slightly older population than papillary cancer. It can spread to distant sites such as the lungs or bones, which has a larger effect on survival than in papillary disease. Overall five-year survival is still high but drops more sharply at advanced stages.

Medullary thyroid cancer accounts for about 5 per cent of cases. It develops from the parafollicular C cells of the thyroid rather than the follicular cells. In around a quarter of cases it is linked to an inherited RET gene mutation and may run in families as part of multiple endocrine neoplasia syndromes (MEN2A, MEN2B) or familial medullary thyroid cancer. This type does not take up radioactive iodine, so treatment and follow-up differ from the differentiated cancers.

Anaplastic thyroid cancer is the rarest type, making up under 2 per cent of diagnoses. It is aggressive, typically affects the oldest patients, and is the most challenging thyroid cancer to treat. Almost all cases are already stage 4 at diagnosis.

How thyroid cancer is staged in 2026 (AJCC 8th edition)

Staging describes how far a cancer has spread at the time of diagnosis. The NHS uses the AJCC (American Joint Committee on Cancer) 8th edition TNM system, which looks at tumour size and extent (T), spread to nearby lymph nodes (N) and spread to distant parts of the body (M).

For papillary and follicular thyroid cancers, known collectively as differentiated thyroid cancers, staging takes age into account in a way that is unusual among cancers. If you are under 55 at diagnosis, only two stages exist: stage 1 means the cancer has not spread to distant sites, regardless of tumour size or lymph node involvement, and stage 2 means there is distant metastatic spread. There is no stage 3 or stage 4 for patients under 55 with differentiated thyroid cancer. This reflects the fact that younger patients with these types do extremely well even when lymph nodes are involved.

For patients aged 55 and over, all four stages apply. Stage 1 means the tumour is contained within the thyroid and is 4 cm or smaller. Stage 2 means it is larger than 4 cm or has minimal spread outside the thyroid. Stage 3 involves spread to nearby structures or certain lymph node groups. Stage 4 means there is spread to distant sites or to critical nearby structures.

Medullary thyroid cancer is staged by TNM without the age-based adjustment, using all four stages based on tumour size, lymph node involvement and distant spread. Anaplastic thyroid cancer is always classified as stage 4 at diagnosis, subdivided into 4A, 4B and 4C depending on how far it has spread locally and whether distant metastases are present.

Papillary thyroid cancer survival by stage

Papillary thyroid cancer is the type most people have, and its survival figures are the most reassuring. The majority of papillary cancers are diagnosed at stage 1 or stage 2, when the tumour is still relatively small and surgery is highly effective.

The approximate five-year survival rates by stage are as follows. At stage 1, around 99 per cent of patients are alive five years after diagnosis. At stage 2, the figure is approximately 97 per cent. Stage 3 sits at around 95 per cent. Stage 4, which means distant metastases are present, drops to around 76 per cent, which is still higher than many other cancers at their most advanced stages.

Ten-year survival remains close to the five-year figures for most stages, reflecting the slow-growing nature of papillary cancer. A person who reaches five years without recurrence has an excellent long-term prognosis.

It is worth noting that even within stage 4 papillary cancer, outcomes are improving. Surgery, radioactive iodine treatment, and more recently targeted therapies for radioiodine-refractory disease mean that many patients with metastatic papillary cancer live for years or even decades after diagnosis. The numbers above are population averages and do not account for individual treatment response, genetic profile or access to newer therapies, all of which may improve on the quoted figures.

Follicular thyroid cancer survival by stage

Follicular thyroid cancer is less common than papillary cancer and tends to be diagnosed in slightly older patients. It can spread through the blood to distant sites such as the lungs, liver and bones, which means that advanced-stage disease has a somewhat wider gap in survival compared to early-stage disease than we see with papillary cancer.

Approximate five-year survival by stage: stage 1 is around 98 per cent, stage 2 is around 95 per cent, stage 3 is around 86 per cent, and stage 4 drops to around 65 per cent. These figures are lower than the equivalent papillary figures at every stage, though still broadly favourable compared to most other cancer types.

The staging system for follicular cancer is the same age-based AJCC 8th edition system used for papillary cancer. Patients under 55 only receive a stage 1 or stage 2 diagnosis, and their prognosis is generally excellent. The lower overall survival figures for follicular cancer are partly driven by the older average age at diagnosis and the higher likelihood of distant metastases.

As with papillary cancer, most follicular cancers respond well to surgery followed by radioactive iodine ablation. The main area where prognosis worsens is when disease becomes radioiodine-refractory, meaning it no longer responds to standard radioactive iodine treatment. In those cases, newer targeted therapies such as lenvatinib are available on the NHS for appropriate patients.

Medullary thyroid cancer survival and the role of RET testing

Medullary thyroid cancer behaves differently from the differentiated types. It arises from a different cell type in the thyroid, does not take up radioactive iodine, and in around 25 per cent of cases is linked to an inherited RET gene mutation.

Approximate five-year survival by stage: stage 1 is around 98 per cent, stage 2 is around 93 per cent, stage 3 is around 75 per cent, and stage 4 is around 39 per cent. The steeper decline at advanced stages compared to papillary and follicular cancer reflects the more aggressive nature of the disease and the more limited treatment options historically.

RET genetic testing is now offered to all patients diagnosed with medullary thyroid cancer. If a hereditary RET mutation is found, first-degree relatives are offered genetic counselling and testing. For children who carry high-risk RET mutations, prophylactic thyroidectomy (removal of the thyroid before cancer develops) may be recommended, sometimes at a very young age depending on the specific mutation.

After treatment, medullary thyroid cancer is monitored using two blood tumour markers: calcitonin and carcinoembryonic antigen (CEA). Rising levels can indicate recurrence before imaging shows anything.

A significant recent advance is selpercatinib, a RET-targeted therapy approved by NICE for NHS use in 2025. It is licensed for patients with RET-altered medullary thyroid cancer that has progressed or is symptomatic. This has changed outcomes for a subset of patients whose disease previously had very limited treatment options.

Anaplastic thyroid cancer: the difficult news

This section contains the hardest numbers in the article, and it would be wrong to soften them beyond what the evidence shows. Anaplastic thyroid cancer is rare, accounting for fewer than 2 per cent of thyroid cancer diagnoses, but it is the most aggressive form and remains extremely difficult to treat.

All anaplastic cancers are classified as stage 4 at diagnosis. The overall five-year survival rate is around 7 per cent. Breaking that down by substage: stage 4A carries approximately 25 per cent five-year survival, stage 4B around 6 per cent, and stage 4C around 3 per cent. The median survival from diagnosis is approximately six months.

These figures are distressing, and they deserve to be stated plainly. Anaplastic thyroid cancer most commonly affects people over 60 and often presents as a rapidly growing neck mass. Because it does not respond to radioactive iodine, treatment relies on surgery where feasible, external beam radiotherapy, chemotherapy and, increasingly, targeted and immunotherapy approaches.

There is some cautious progress. For patients whose tumour carries a BRAF V600E mutation, the combination of dabrafenib and trametinib is now available on the NHS and has shown meaningful tumour responses in some cases. Immunotherapy may be considered for PD-L1 positive disease. These are not cures for most patients, but they represent a shift from the near-total treatment vacuum that existed only a few years ago. Clinical trials remain important for this type.

How NHS treatment shapes survival in 2026

The survival figures quoted above are the product of NHS treatment as well as the biology of each cancer type. Understanding what treatment involves helps put the numbers in context.

NHS treatment for thyroid cancer typically combines surgery, radioactive iodine, and lifelong levothyroxine to achieve some of the best survival outcomes of any cancer.

For differentiated thyroid cancers (papillary and follicular), surgery is the first step. This is usually a hemithyroidectomy (removal of one lobe) for low-risk, small tumours, or a total thyroidectomy for larger or higher-risk disease. For higher-risk cases, radioactive iodine (I-131) ablation follows surgery to destroy any remaining thyroid tissue or microscopic disease.

After surgery, nearly all patients take levothyroxine for life to replace the thyroid hormone the gland would normally produce. In higher-risk disease, the dose is deliberately set to suppress thyroid-stimulating hormone (TSH), typically below 0.1 mU per litre, because TSH can stimulate any remaining cancer cells to grow. In lower-risk patients, a less suppressed TSH target is used.

Lifelong follow-up includes regular blood tests for thyroglobulin (a protein produced by thyroid tissue that acts as a tumour marker in differentiated cancers) and periodic neck ultrasound scans. The schedule is typically more frequent in the first few years and then annual for low-risk patients thereafter.

For medullary cancer, total thyroidectomy with central neck dissection is standard, and calcitonin and CEA are monitored instead of thyroglobulin. Selpercatinib, approved by NICE in 2025, is now available for RET-altered medullary cancer that has progressed or is symptomatic, adding a targeted option where one did not previously exist on the NHS.

Recurrence rates and lifelong follow-up

A diagnosis of thyroid cancer does not end once initial treatment is complete. The NHS provides structured, long-term follow-up because recurrence, while usually treatable, is a real possibility.

For differentiated thyroid cancers, the recurrence rate is approximately 10 to 30 per cent over ten years, depending on initial stage and risk factors. Importantly, most recurrences are local, appearing in the thyroid bed or in lymph nodes in the neck, and can be treated effectively with further surgery or additional radioactive iodine. Distant recurrence, such as in the lungs or bones, is less common and more serious but still manageable in many cases with ongoing treatment.

Medullary thyroid cancer recurrence rates sit at around 20 to 30 per cent. Calcitonin and CEA levels are checked regularly to detect recurrence early, sometimes before it shows on a scan.

The typical NHS follow-up schedule involves appointments every three months in the first year, every six months in years two and three, and annually thereafter for low-risk patients. At each visit, blood tests and clinical assessment guide whether further imaging is needed. This may sound like a lot of appointments, but they become routine for most people and provide ongoing reassurance.

It is worth knowing that a recurrence is not the same as a new diagnosis. Recurrent differentiated thyroid cancer is usually caught at a treatable stage precisely because of the follow-up programme, and many patients who experience recurrence go on to live for many years afterwards.

Frequently Asked Questions

Is thyroid cancer always treatable in the UK?

The most common types, papillary and follicular thyroid cancer, are highly treatable with surgery, radioactive iodine and levothyroxine. Cure rates are among the highest of any cancer. Anaplastic thyroid cancer is the exception and remains very difficult to treat, though new targeted therapies are beginning to make a difference for some patients. The earlier the diagnosis is made, the better the outlook tends to be across all types.

What does 5-year survival rate actually mean?

A five-year survival rate is the percentage of people with that type and stage of cancer who are still alive five years after diagnosis, compared to people of the same age and sex in the general population. It is a population-level statistic gathered over years, not a prediction for one individual. Your own prognosis depends on your specific type, stage, age, genetics and how your cancer responds to treatment.

Does the new selpercatinib drug work for everyone with thyroid cancer?

No. Selpercatinib is specifically licensed for RET-altered medullary thyroid cancer and RET-fusion-positive radioiodine-refractory differentiated thyroid cancer. It was approved by NICE for NHS use in 2025. It requires confirmed RET genetic testing of the tumour before it can be prescribed, so it is only available to a defined subset of patients whose cancers carry the relevant genetic change.

Will I need lifelong levothyroxine after thyroid cancer surgery?

Yes, if you have a total thyroidectomy. The dose is carefully adjusted to keep your TSH at a target level, which is often suppressed below 0.1 mU per litre in higher-risk disease and less suppressed in lower-risk cases. Levothyroxine is free of charge in Scotland, Wales and Northern Ireland. In England, thyroid cancer patients qualify for a medical exemption certificate, so prescriptions are free.

How likely is thyroid cancer to come back?

Recurrence of differentiated thyroid cancer occurs in roughly 10 to 30 per cent of patients over ten years, depending on the initial stage and risk profile. Medullary thyroid cancer recurrence rates are around 20 to 30 per cent. Most recurrences are local or involve lymph nodes in the neck, and they can be treated effectively with further surgery or radioactive iodine. The structured NHS follow-up programme is designed to catch recurrence early.

Why is thyroid cancer more common in women?

The reasons are not fully understood. Hormonal factors, including the influence of oestrogen and changes during pregnancy, are thought to play a role. Some researchers suggest that women may detect neck lumps earlier because of routine breast and neck examination during healthcare visits. The three-to-one female-to-male ratio appears in adolescence and persists throughout adult life. Outcomes are slightly better in women, partly because of the younger average age at diagnosis.

Should my family be tested if I have medullary thyroid cancer?

Yes. RET gene testing is offered to all patients with medullary thyroid cancer. If a hereditary RET mutation is identified, first-degree relatives should be referred for genetic counselling and testing. For children found to carry high-risk RET mutations, prophylactic thyroidectomy is considered, sometimes in early childhood for the highest-risk mutations. Early detection through family screening can prevent cancer from developing at all.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.